Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients

Journal of the National Cancer Institute

Volumn 104, Issue 23, 2012, Pages 1796-1807

  Chew, Valerie ^a   Tow, Charlene ^a   Huang, Caleb ⁱ   Bard Chapeau, Emilie ^b   Copeland, Neal G ^b   Jenkins, Nancy A ^b   Weber, Achim ^c   Lim, Kiat Hon ^d   Toh, Han Chong ^e   Heikenwalder, Mathias ^f,g   Ng, Irene Oi Lin ^h   Nardin, Alessandra ^a   Abastado, Jean Pierre ^a  

^a AGENCY FOR SCIENCE   (Singapore)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

^e DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h QUEEN MARY HOSPITAL   (Hong Kong)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; TOLL LIKE RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER TISSUE; CELL ACTIVATION; CELL DEATH; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOPATHOGENIC EFFECT; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REGULATORY MECHANISM; SURVIVAL RATE;

ADULT; AGED; ANALYSIS OF VARIANCE; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KILLER CELLS, NATURAL; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MICE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; POLYMERASE CHAIN REACTION; TOLL-LIKE RECEPTOR 3;

EID: 84870915632     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs436     Document Type: Article

References (32)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907-1917.
2. Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene. 2006;25(27):3823-3833.
3. Nakamoto Y, Guidotti LG, Kuhlen C.V., Fowler P., Chisari F V. Immune pathogenesis of hepatocellular carcinoma. J Exp Med. 1998;188(2):341-350.
4. Chew V, Tow C, Teo M, et al Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol. 2010;52(3):370-379.
5. Matsumoto M, Funami K, Tanabe M., et al Subcellular localization of Tolllike receptor 3 in human dendritic cells. J Immunol. 2003;171(6):3154-3162.
6. Pisegna S, Pirozzi G, Piccoli M., Frati L, Santoni A, Palmieri G. p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells. Blood. 2004;104(13):4157-4164.
7. Farina GA, York MR, Di Marzio M, et al Poly(I:C) drives type I IFN-and TGFβ-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. J Invest Dermatol. 2010;130(11): 2583-2593.
8. Guillot L, Le Goffic R, Bloch S, et al Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem. 2005;280(7):5571-5580.
9. Li K, Chen Z, Kato N., Gale M Jr, Lemon SM Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J Biol Chem. 2005;280(17):16739-16747.
10. Salaun B, Coste I, Rissoan M.C., Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol. 2006;176(8):4894-4901.
11. Salaun B, Lebecque S, Matikainen S., Rimoldi D, Romero P. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res. 2007;13(15, pt 1):4565-4574.
12. Matsumoto M, Funami K, Oshiumi H., Seya T. Toll-like receptor 3: a link between toll-like receptor, interferon and viruses. Microbiol Immunol. 2004; 48(3):147-154.
13. Beg AA. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol. 2002;23(11): 509-512.
14. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006;6(11):823-835.
15. Salem ML, Kadima AN, Cole D.J., Gillanders WE Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother. 2005;28(3):220-228.
16. Schulz O, Diebold SS, Chen M, et al Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature. 2005;433(7028):887-892.
17. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy. 2009;1(6):949-964.
18. Khvalevsky E, Rivkin L, Rachmilewitz J., Galun E, Giladi H. TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem. 2007;100(5):1301-1312.
19. Schmidt KN, Leung B, Kwong M., et al APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA. J Immunol. 2004;172(1):138-143.
20. Chew V, Chen J, Lee D., et al Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut. 2012;61(3):427-438.
21. McCartney S, Vermi W, Gilfillan S., et al Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med. 2009;206(13):2967-2976.
22. Chisari F.V., Klopchin K, Moriyama T., et al Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell. 1989;59(6):1145-1156.
23. Keng VW, Villanueva A, Chiang D.Y., et al A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol. 2009;27(3):264-274.
24. Hong M, Puaux AL, Huang C, et al Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res. 2011;71(22):6997-7009.
25. Yu L, Chen S. Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother. 2008;57(9):1271-1278.
26. Sauder DN. The emerging role of immunotherapy in the treatment of non-melanoma skin cancers. Nat Clin Pract Oncol. 2005;2(7):326-327.
27. Murad YM, Clay TM CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer. BioDrugs. 2009;23(6):361-375.
28. Salaun B, Zitvogel L, Asselin-Paturel C, et al TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res. 2011;71(5):1607-1614.
29. Hawkins MJ, Levin M, Borden EC An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma. J Biol Response Mod. 1985;4(6):664-668.
30. Yoneda K, Sugimoto K, Shiraki K., et al Dual topology of functional Tolllike receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-kappaB activation and apoptosis. Int J Oncol. 2008;33(5):929-936.
31. Sivori S, Falco M, Carlomagno S., Romeo E, Moretta L, Moretta A. Heterogeneity of TLR3 mRNA transcripts and responsiveness to poly (I:C) in human NK cells derived from different donors. Int Immunol. 2007;19(12): 1341-1348.
32. Lang KS, Georgiev P, Recher M., et al Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J Clin Invest. 2006;116(9): 2456-2463.